Registry analysis suggests women often receive too much treatment with glycoprotein 2B3A inhibitors. Duke University’s Karen Alexander told us more.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.